BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chemo cocktail aims to shrink pancreatic tumors before surgery
Disease control Recruiting nowThis study tests whether giving a combination of chemotherapy drugs (NALIRIFOX) before surgery can help shrink pancreatic tumors that are close to major blood vessels but still removable. About 20 adults with this type of pancreatic cancer will receive the treatment to see if it …
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
New proton beam strategy aims to tame tough pancreatic tumors
Disease control Recruiting nowThis study tests a new way of giving radiation called PULSAR, which delivers short, powerful proton beam pulses spaced weeks apart. The goal is to better control pancreatic tumors while reducing side effects. About 47 adults with locally advanced or limited spread pancreatic canc…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New chemo cocktail aims to shrink pancreatic tumors before surgery
Disease control Recruiting nowThis study tests whether giving a combination of three chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel) before surgery can help shrink pancreatic tumors and improve outcomes. About 36 adults with pancreatic cancer that can be surgically removed will participate. Th…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Genetic clues could unlock better pancreatic cancer care
Knowledge-focused Recruiting nowThis study looks at whether genetic information from tumors can help doctors choose the right treatment for pancreatic cancer. About 200 people with early or locally advanced pancreatic cancer will give blood and tissue samples while receiving standard chemotherapy. Researchers w…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated May 17, 2026 03:12 UTC
-
New study peeks inside pancreatic tumors to find better drug targets
Knowledge-focused Recruiting nowThis study is for people with pancreatic cancer that can be removed by surgery or has spread. Researchers will give one of several drugs (cobimetinib, olaparib, onvansertib, azenosertib, AZD5305, or tremelimumab) for a short time before surgery or biopsy. By comparing tumor sampl…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 17, 2026 03:09 UTC